Bosutinib is a second-generation dual SRC/ABL TKI, approximately 10–30 times more potent than imatinib, and it was recently approved by FDA as a second line option for CML treatment [4]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.